Recent data from the Hong Kong Stock Exchange reveals a significant transaction involving a leading biopharmaceutical firm.
On June 10th, Fullgoal Fund Management Co., Ltd. increased its stake in 3SBIO (01530) by purchasing 636,500 shares.
The transaction was executed at an average price of approximately HK$16.28 per share, resulting in a total investment of around HK$10.36 million.
Following this acquisition, Fullgoal Fund Management's total shareholding in the company has risen to approximately 178 million shares, representing a 7% ownership stake.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments